title: Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?
abstract: This review considers the treatment for combined hyperlipidaemia (CH) with a combination formulation of three drugs: a statin, nicotinic acid (NA) and aspirin--a mini-polypill. CH is a highly atherogenic dyslipidaemia manifested either as familial combined hyperlipidaemia or dyslipidaemia related to the metabolic syndrome or Type 2 diabetes mellitus. These types of dyslipidaemia are highly prevalent in the general population. Statin plus extended-release NA is a promising treatment option for the normalisation of these atherogenic lipid alterations, regression of atherosclerosis, as well as for primary or secondary prevention of cardiovascular disease (CVD) events. The addition of aspirin might prove a useful adjunct that might reduce the cutaneous side effects of NA while also acting as an antiplatelet agent in high-CVD-risk patients. However, the effective dose of aspirin may need to be at least 160 mg/day. This triple combination might improve patient compliance when compared with the three drugs administered separately.
authors.affiliation: Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Thessaloniki, Greece.
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Tziomalos
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
authors.forename: Efstathios D
authors.initials: ED
authors.lastname: Pagourelias
authors.forename: Anna I
authors.initials: AI
authors.lastname: Kakafika
authors.forename: Athanasios
authors.initials: A
authors.lastname: Skaperdas
authors.forename: Apostolos
authors.initials: A
authors.lastname: Hatzitolios
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
mesh_terms: D001241:Aspirin / Q000008:administration & dosage*; D004338:Drug Combinations; D050171:Dyslipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D006301:Health Services Needs and Demand / Q000639:trends; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006950:Hyperlipidemia, Familial Combined / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006949:Hyperlipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D009525:Niacin / Q000008:administration & dosage*
chemical_list: D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin; D001241:Aspirin